Suppr超能文献

鉴定突变型 p53 获得功能所必需的功能结构域。

Characterization of functional domains necessary for mutant p53 gain of function.

机构信息

Comparative Cancer Center, University of California, Davis, CA 95616, USA.

出版信息

J Biol Chem. 2010 May 7;285(19):14229-38. doi: 10.1074/jbc.M109.097253. Epub 2010 Mar 8.

Abstract

Tumor cells, including SW480 carcinoma cells that carry a mutant p53, are addicted to the mutant for their survival and resistance to growth suppression by chemotherapeutic agents. Here, we investigated whether various classes of p53 mutants share a common property and functional domains necessary for mutant p53 gain of function. To test this, we generated SW480 cell lines in which endogenous mutant R273H/P309S can be inducibly or stably knocked down, whereas a small interfering RNA-resistant mutant p53 along with a mutated functional domain can be inducibly or stably expressed. We found that both contact-site (R248W and R273H) and conformation (G245S and R249S) mutants are able to maintain the transformed phenotypes of SW480 cells conferred by endogenous mutant p53. We also found that activation domains 1-2 and the proline-rich domain are required for mutant p53 gain of function. Interestingly, we showed that the C-terminal basic domain, which is required for wild-type p53 activity, is an inhibitory domain for mutant p53. Furthermore, we showed that deletion of the basic domain enhances, whereas a mutation in activation domains 1-2 and deletion of the proline-rich domain abolish mutant p53 to regulate Gro1 and Id2, both of which are regulated by and mediate endogenous mutant p53 gain of function. These results indicate that both conformation and contact-site mutants share a property for cell transformation, and the domains critical for wild-type p53 tumor suppression are also required for mutant p53 tumor promotion. Thus, the inhibitory basic domain and the common property for p53 mutants can be explored for targeting tumors with mutant p53.

摘要

肿瘤细胞,包括携带突变 p53 的 SW480 癌细胞,依赖于突变体来生存并抵抗化疗药物的生长抑制。在这里,我们研究了不同类别的 p53 突变体是否具有共同的性质和功能域,这些性质和功能域对于突变 p53 的功能获得是必要的。为了测试这一点,我们生成了 SW480 细胞系,其中内源性突变体 R273H/P309S 可以被诱导或稳定敲低,而一个小干扰 RNA 抗性的突变 p53 以及一个突变的功能域可以被诱导或稳定表达。我们发现,接触位点(R248W 和 R273H)和构象(G245S 和 R249S)突变体都能够维持内源性突变 p53赋予 SW480 细胞的转化表型。我们还发现,激活域 1-2 和富含脯氨酸的结构域对于突变 p53 的功能获得是必需的。有趣的是,我们表明,对于野生型 p53 活性是必需的 C 端碱性结构域是突变 p53 的抑制结构域。此外,我们表明碱性结构域的缺失增强了,而激活域 1-2 的突变和富含脯氨酸结构域的缺失则消除了突变 p53 对 Gro1 和 Id2 的调节作用,这两种蛋白都受到内源性突变 p53 功能获得的调节并介导其作用。这些结果表明,构象和接触位点突变体都具有细胞转化的性质,对于野生型 p53 肿瘤抑制至关重要的结构域也对于突变 p53 的肿瘤促进是必需的。因此,突变 p53 的抑制碱性结构域和共同性质可以被探索用于靶向携带突变 p53 的肿瘤。

相似文献

1
Characterization of functional domains necessary for mutant p53 gain of function.
J Biol Chem. 2010 May 7;285(19):14229-38. doi: 10.1074/jbc.M109.097253. Epub 2010 Mar 8.
2
3
Identification of GRO1 as a critical determinant for mutant p53 gain of function.
J Biol Chem. 2009 May 1;284(18):12178-87. doi: 10.1074/jbc.M900994200. Epub 2009 Mar 3.
4
P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
J Exp Clin Cancer Res. 2019 Aug 28;38(1):379. doi: 10.1186/s13046-019-1375-9.
5
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.
J Biol Chem. 2010 May 7;285(19):14160-9. doi: 10.1074/jbc.M109.094813. Epub 2010 Mar 11.
7
Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30.
8
SW480, a p53 double-mutant cell line retains proficiency for some p53 functions.
J Mol Biol. 2005 Sep 9;352(1):44-57. doi: 10.1016/j.jmb.2005.06.033.
9
10
Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.
J Cell Sci. 2012 Jul 1;125(Pt 13):3144-52. doi: 10.1242/jcs.099663. Epub 2012 Mar 16.

引用本文的文献

2
Osteosarcoma patient with Li-Fraumeni syndrome: the first case report in Vietnam.
Front Oncol. 2024 Oct 8;14:1458232. doi: 10.3389/fonc.2024.1458232. eCollection 2024.
3
Knockdown of TFAP2E results in rapid G/M transition in oral squamous cell carcinoma cells.
Oncol Lett. 2024 Jan 29;27(3):128. doi: 10.3892/ol.2024.14260. eCollection 2024 Mar.
4
Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis.
Oncogene. 2019 Aug;38(35):6256-6269. doi: 10.1038/s41388-019-0876-5. Epub 2019 Jul 22.
5
Gain-of-function mutant p53: history and speculation.
J Mol Cell Biol. 2019 Jul 19;11(7):605-609. doi: 10.1093/jmcb/mjz067.
6
Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
Mol Cell Biol. 2019 Feb 4;39(4). doi: 10.1128/MCB.00375-18. Print 2019 Feb 15.
7
Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a026054. doi: 10.1101/cshperspect.a026054.
8
TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
J Cell Biochem. 2016 Dec;117(12):2682-2692. doi: 10.1002/jcb.25592. Epub 2016 Jun 3.
9
Mutant p53 and ETS2, a Tale of Reciprocity.
Front Oncol. 2016 Feb 18;6:35. doi: 10.3389/fonc.2016.00035. eCollection 2016.
10
Mutant p53: One, No One, and One Hundred Thousand.
Front Oncol. 2015 Dec 21;5:289. doi: 10.3389/fonc.2015.00289. eCollection 2015.

本文引用的文献

1
p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors.
Cell Death Differ. 2010 Mar;17(3):540-50. doi: 10.1038/cdd.2009.136. Epub 2009 Sep 25.
2
20 years studying p53 functions in genetically engineered mice.
Nat Rev Cancer. 2009 Nov;9(11):831-41. doi: 10.1038/nrc2731. Epub 2009 Sep 24.
3
The first 30 years of p53: growing ever more complex.
Nat Rev Cancer. 2009 Oct;9(10):749-58. doi: 10.1038/nrc2723.
4
Transcription activity is required for p53-dependent tumor suppression.
Oncogene. 2009 Dec 10;28(49):4397-401. doi: 10.1038/onc.2009.290.
5
When mutants gain new powers: news from the mutant p53 field.
Nat Rev Cancer. 2009 Oct;9(10):701-13. doi: 10.1038/nrc2693. Epub 2009 Aug 20.
6
Blinded by the Light: The Growing Complexity of p53.
Cell. 2009 May 1;137(3):413-31. doi: 10.1016/j.cell.2009.04.037.
7
Identification of GRO1 as a critical determinant for mutant p53 gain of function.
J Biol Chem. 2009 May 1;284(18):12178-87. doi: 10.1074/jbc.M900994200. Epub 2009 Mar 3.
8
9
A role for caspase 2 and PIDD in the process of p53-mediated apoptosis.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1937-42. doi: 10.1073/pnas.0711800105. Epub 2008 Jan 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验